ArticleeLife2022
Closely related type II-C Cas9 orthologs recognize diverse PAMs.
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Customizing CRISPR-Cas PAM specificity with protein language models.Nature biotechnology · 2026Article
- An anti-CRISPR targets the sgRNA to block Cas9 and guides the design of enhanced genome editors.Nature structural & molecular biology · 2026Article
- In vivo genome editing with a novel Cj4Cas9.Communications biology · 2025Article
- Article
- And… cut! - how conformational regulation of CRISPR-Cas effectors directs nuclease activity.The Biochemical journal · 2025Review
- Off-target interactions in the CRISPR-Cas9 Machinery: mechanisms and outcomes.Biochemistry and biophysics reports · 2025Review
- Engineering of SauriCas9 with enhanced specificity.Molecular therapy. Nucleic acids · 2025Article
- Insight into crRNA Processing inInternational journal of molecular sciences · 2025Article
- Enhanced genome editing with a Streptococcus equinus Cas9.Communications biology · 2025Article
- Engineering of CRISPR-Cas PAM recognition using deep learning of vast evolutionary data.bioRxiv : the preprint server for biology · 2025Article
- Rational Design of Enhanced Nme2Cas9 and Nme2bioRxiv : the preprint server for biology · 2024Article
- Accelerated discovery and miniaturization of novel single-stranded cytidine deaminases.Nucleic acids research · 2024Article
- Characterization of NiCas12b for In Vivo Genome Editing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Engineering of a high-fidelity Cas12a nuclease variant capable of allele-specific editing.PLoS biology · 2024Article
- Discovery and engineering of Tsp2Cas9 for genome editing.Cell discovery · 2024Article
- Domain-inlaid Nme2Cas9 adenine base editors with improved activity and targeting scope.Nature communications · 2024Article
- Engineered domain-inlaid Nme2Cas9 adenine base editors with increased on-target DNA editing and targeting scope.BMC biology · 2023Article
- CRISPR/Cas9 Landscape: Current State and Future Perspectives.International journal of molecular sciences · 2023Review
- Computational design of novel Cas9 PAM-interacting domains using evolution-based modelling and structural quality assessment.PLoS computational biology · 2023Article
- Engineering aACS synthetic biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The RNA-guided CRISPR/Cas9 system is a powerful tool for genome editing, but its targeting scope is limited by the protospacer-adjacent motif (PAM). To expand the target scope, it is crucial to develop a CRISPR toolbox capable of recognizing multiple PAMs. Here, using a GFP-activation assay, we tested the activities of 29 type II-C orthologs closely related to Nme1Cas9, 25 of which are active in human cells. These orthologs recognize diverse PAMs with variable length and nucleotide preference, including purine-rich, pyrimidine-rich, and mixed purine and pyrimidine PAMs. We characterized in depth the activity and specificity of Nsp2Cas9. We also generated a chimeric Cas9 nuclease that recognizes a simple N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.